Etiology of Lymphopenia in Covid19 Infection

NCT ID: NCT04404608

Last Updated: 2022-07-20

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

172 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-06-01

Study Completion Date

2021-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Study of the cause of lymphopenia in Covid19 viral infection will be done in 3 cohorts. First cohort will be patients asymptomatic or with mild symptoms. Second cohort will be patients with severe illness and admitted to ICU. Third cohort will be patients critically ill and on artificial ventilation.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Each cohort will include 30 patients. Complete blood count in all patients will be done daily in all patients. Bone marrow aspiration cytology will be done in some selected patients especially those with lymphopenia less than 1000 per cubic mm.

Correlation of the degree of lymphopenia with the status of the patients will be done. Also correlation will be done about the relation of recovery of lymphopenia and status of the patients.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lymphopenia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Asymptomatic or mild symptoms patients patients

Patients with no or mild symptoms and need no respiratory support.

Complete blood picture, bone marrow aspiration cytology

Intervention Type DIAGNOSTIC_TEST

none except the regular routine investigations in such cases

Severe symptoms patients

Patients who need admission to ICU because he needs oxygen by nasal canula and needs drugs whether azthromycin or remdesivir according to treatment protocol.

Complete blood picture, bone marrow aspiration cytology

Intervention Type DIAGNOSTIC_TEST

none except the regular routine investigations in such cases

Critically ill patients

Patients who need artificial ventilation because of many causes and may need plasma from convalescent patients

Complete blood picture, bone marrow aspiration cytology

Intervention Type DIAGNOSTIC_TEST

none except the regular routine investigations in such cases

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Complete blood picture, bone marrow aspiration cytology

none except the regular routine investigations in such cases

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Any patient admitted with the diagnosis of Covid19 viral infection

Exclusion Criteria

* Any patient who died within one day of admission
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Dr Medhat Khafagy

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Dr Medhat Khafagy

professor of surgical oncology

Responsibility Role SPONSOR_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

National Cancer Institute Cairo University

Cairo, , Egypt

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

201920008.2

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

FMF and Atheroscelerosis
NCT06047938 UNKNOWN
Cell Free DNA in Cardiac Sarcoidosis
NCT03858777 RECRUITING NA